Carbidopa/Levodopa

Researchers report successful treatment of ciltacabtagene autoleucel-induced parkinsonism in multiple myeloma patients using the JAK inhibitor ruxolitinib, offering a potential solution for this serious complication.

BioVie has enrolled the first patient in its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms of long COVID, with topline data expected in the first half of 2026.

BioVie has enrolled the first patient in its Phase 2 SUNRISE-PD trial evaluating bezisterim, an anti-inflammatory and insulin-sensitizing drug candidate, in early-stage Parkinson's disease patients who haven't received carbidopa/levodopa treatment.

New Phase 3 RISE-PD study data reveals CREXONT (carbidopa/levodopa extended-release) significantly improved sleep quality in Parkinson's disease patients compared to immediate-release formulations, with a mean difference of -2.35 in PDSS-2 scores (p<0.0001).

AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach.